Ribociclib + adjuvant hormone therapy in early breast cancer: prevention of recurrence. New opportunities. A review

Cover Page

Cite item

Full Text

Abstract

Breast cancer (BC) occupies a leading position among all malignant neoplasms in women worldwide and is the 4th deadliest. Most cases are diagnosed in stages I–III. Among the molecular biological variants, luminal HER2 negative (HER2-) prevails, accounting for 70–75%. Currently, therapies combining surgery with chemotherapy and, more rarely, radiation therapy, followed by adjuvant hormone therapy for up to 10 years, are a standard of care in BC. The goal of these regimens is the prevention of early recurrence in patients in the high-risk group with a primary hormone-resistant tumor. However, at the end of treatment, it occurs in 27–57% of patients with stage II–III breast cancer. For its prevention in early HR-positive (HR+) HER2- BC, an innovative class of drugs, cyclin-dependent kinase 4/6 inhibitors, is used combined with hormone therapy (aromatase inhibitors, anti-estrogens, gonadotropin-releasing hormone agonists), which is the subject of a randomized phase III NATALEE study evaluating the efficacy and safety of ribociclib in combination with endocrine therapy in early non-metastatic BC. The study enrolled patients with stage II–III breast cancer, including those with N0. Patients of the study group received ribociclib at a dose of 400 mg/day for 21 days in combination with aromatase inhibitors, and in the control group, only aromatase inhibitors. The median follow-up was 34 months. Three-year survival without invasive disease was 90.7% in the ribociclib group and 87.6% in controls. The risk of distant metastasis and invasive diseases was reduced by 25.1% in the ribociclib group. Therefore, ribociclib tended to improve overall survival. The initial dose of 400 mg/day reduced the incidence of adverse events; the most common were neutropenia (62.5%), arthralgia (37.3%) and hepatic toxicity (26.4%). The most common reasons for discontinuing ribociclib were hepatic toxicity (8.9%) and arthralgia (1.3%). The results demonstrate a statistical and clinical superiority of ribociclib in combination with hormone therapy in the treatment of early HR+ HER2- breast cancer with a high risk of recurrence.

About the authors

Nikolai A. Ognerubov

Penza Institute for Advanced Training of Physicians – branch of the Russian Medical Academy of Continuous Professional Education

Author for correspondence.
Email: ognerubov_n.a@mail.ru
ORCID iD: 0000-0003-4045-1247

D. Sci. (Med.), Cand. Sci. (Law), Prof.

Russian Federation, Penza

References

  1. Globocan cancer observatory. 2020. Available at: https://gco.iarc.fr. Accessed: 09.09.2023.
  2. Dafni U, Tsourti Z, Alatsathianos I. Breast Cancer Statistics in the European Union: Incidence and Survival across European Countries. Breast Care (Basel). 2019;14(6):344-53. doi: 10.1159/000503219
  3. Burstein HJ, Curigliano G, Thürlimann B, et al. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol. 2021;32(10):1216-35. doi: 10.1016/j.annonc.2021.06.023
  4. Gomis RR, Gawrzak S. Tumor cell dormancy. Mol Oncol. 2017;11(1):62-78. doi: 10.1016/j.molonc.2016.09.009
  5. National Comprehensive Cancer Network. Breast Cancer. Available at: http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed: 17.06.2022.
  6. National Comprehensive Cancer Network. Breast Cancer (version 4.2020). Available at: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf Google Scholar. Accessed: 17.06.2022.
  7. Jakesz R, Greil R, Gnant M, et al. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst. 2007;99(24):1845-53. doi: 10.1093/jnci/djm246
  8. Howell A. Adjuvant aromatase inhibitors for breast cancer. Lancet. 2005;366(9484):431-3. doi: 10.1016/S0140-6736(05)67036-5
  9. Cardoso F, Senkus E, Costa A, et al. 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4). Ann Oncol. 2018;29(8):1634-57. doi: 10.1093/annonc/mdy192
  10. Sledge GW Jr, Toi M, Neven P, et al. The effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed On Endocrine Therapy – MONARCH 2: A Randomized Clinical Trial. JAMA Oncol. 2020;6(1):116-24. doi: 10.1001/jamaoncol.2019.4782
  11. Slamon DJ, Neven P, Chia S, et al. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. J Clin Oncol. 2018;36(24):2465-72. doi: 10.1200/JCO.2018.78.9909
  12. Johnston S, Martin M, Di Leo A, et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer. 2019;5:5. doi: 10.1038/s41523-018-0097-z
  13. Tripathy D, Im SA, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19(7):904-15. doi: 10.1016/S1470-2045(18)30292-4
  14. Dickler MN, Tolaney SM, Rugo HS, et al. MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer. Clin Cancer Res. 2017;23:5218-24. doi: 10.1158/1078-0432.CCR-17-0754
  15. Sledge GW Jr, Toi M, Neven P, et al. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. J Clin Oncol. 2017;35:2875-84. doi: 10.1200/JCO.2017.73.7585
  16. Goetz MP, Toi M, Campone M, et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol. 2017;35(32):3638-46. doi: 10.1200/JCO.2017.75.6155
  17. O’Leary B, Finn RS, Turner NC. Treating cancer with selective CDK4/6 inhibitors. Nat Rev Clin Oncol. 2016;13(7):417-30. doi: 10.1038/nrclinonc.2016.26
  18. Santo L, Siu KT, Raje N. Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers. Semin Oncol. 2015;42(6):788-800. doi: 10.1053/j.seminoncol.2015.09.024
  19. Klein ME, Kovatcheva M, Davis LE, et al. CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought. Cancer Cell. 2018;34(1):9-20. doi: 10.1016/j.ccell.2018.03.023
  20. Lange CA, Yee D. Killing the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer. Endocr Relat Cancer. 2011;18(4):19-24. doi: 10.1530/ERC-11-0112
  21. Li H, Zheng B. Overexpression of the Ubiquitin-Specific Peptidase 9 X–Linked (USP9X) Gene is Associated with Upregulation of Cyclin D1 (CCND1) and Downregulation of Cyclin-Dependent Inhibitor Kinase 1A (CDKN1A) in Breast Cancer Tissue and Cell Lines. Med Sci Monit. 2019;25:4207-16. doi: 10.12659/MSM.914742
  22. Classon M, Harlow E. The retinoblastoma tumour suppressor in development and cancer. Nat Rev Cancer. 2002;2(12):910-7. doi: 10.1038/nrc950
  23. Ding L, Cao J, Lin W, et al. The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer. Int J Mol Sci. 2020;21(6):1960. doi: 10.3390/ijms21061960
  24. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-74. doi: 10.1016/j.cell.2011.02.013
  25. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9(3):153-66. doi: 10.1038/nrc2602
  26. Laurenti E, Frelin C, Xie S, et al. CDK6 levels regulate quiescence exit in human hematopoietic stem cells. Cell Stem Cell. 2015;16(3):302-13. doi: 10.1016/j.stem.2015.01.017
  27. Chen P, Lee NV, Hu W, et al. Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance. Mol Cancer Ther. 2016;15(10):2273-81. doi: 10.1158/1535-7163.MCT-16-0300
  28. Finn RS, Martin M, Rugo HS, et al. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med. 2016;375(20):1925-36. doi: 10.1056/NEJMoa1607303
  29. Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med. 2016;375(18):1738-48. doi: 10.1056/NEJMoa1609709
  30. Turner NC, Slamon DJ, Ro J, et al. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. N Engl J Med. 2018;379(20):1926-36. doi: 10.1056/NEJMoa1810527
  31. Slamon DJ, Neven P, Chia S, et al. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. N Engl J Med. 2020;382(6):514-24. doi: 10.1056/NEJMoa1911149
  32. Braal CL, Jongbloed EM, Wilting SM, et al. Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences. Drugs. 2021;81(3):317-31. doi: 10.1007/s40265-020-01461-2
  33. Hortobagyi GN, Stemmer SM, Burris HA, et al. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. N Engl J Med. 2022;386(10):942-50. doi: 10.1056/NEJMoa2114663
  34. Finn R, Rugo H, Dieras V, et al. Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer (ER+/HER2– ABC): Analyses from PALOMA-2. J Clin Oncol. 2022;40(17_suppl.):LBA1003.
  35. Goetz M. MONARCH 3: Final overall survival results of abemaciclib plus a nonsteroidal aromatase inhibitor as first-line therapy in patients with HR+, HER2- advanced breast cancer. Presented at SABCS 2023 (December 06). GS01-12. abstract 1643629. Available at: http://www.sabcs.org. Accessed: 13.09.2023.
  36. Lu YS, Im SA, Colleoni M, et al. Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial. Clin Cancer Res. 2022;28(5):851-9. doi: 10.1158/1078-0432.CCR-21-3032
  37. Yardley DA, Yap YS, Azim HA, et al. 205P Pooled exploratory analysis of survival in patients (pts) with HR+/HER2- advanced breast cancer (ABC) and visceral metastases (mets) treated with ribociclib (RIB) + endocrine therapy (ET) in the MONALEESA (ML) trials. Ann Oncol. 2022;33(Suppl. 7):S629. doi: 10.1016/j.annonc.2022.07.239
  38. Iqbal J, Ginsburg O, Rochon PA, et al. Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. JAMA. 2015;313(2):165-73. doi: 10.1001/jama.2014.17322
  39. Pan H, Gray R, Braybrooke J, et al. 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. N Engl J Med. 2017;377(19):1836-46. doi: 10.1056/NEJMoa1701830
  40. Gnant M, Dueck AC, Frantal S, et al. Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). J Clin Oncol. 2022;40(3):282-93. doi: 10.1200/JCO.21.02554
  41. Johnston SRD, Toi M, O’Shaughnessy J, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023;24(1):77-90. doi: 10.1016/S1470-2045(22)00694-5
  42. Johnston SRD, Harbeck N, Hegg R, et al. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE). J Clin Oncol. 2020;38(34):3987-98. doi: 10.1200/JCO.20.02514
  43. Eli Lilly and Company release. Landmark 5-Year monarchE Outcome Data Demonstrate Verzenio® (abemaciclib)’s Long-Term Impact on Cancer Recurrence in High-Risk Early Breast Cancer. October 20, 2023. Available at: https://investor.lilly.com/news-releases/news-release-details/landmark-5-year-monarche-outcome-data-demonstrate-verzenior. Accessed: 20.09.2023.
  44. Harbeck N, Rastogi P, Martin M, et al. Adjuvant Abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study the monarchE study. Ann Oncol. 2021;32(12):1571-81. doi: 10.1016/j.annonc.2021.09.015
  45. Harbeck N, Rastogi P, O’Shaughnessy J, et al. Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: Results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes. Ann Oncol. 2023;34(S2):S1255-S56. doi: 10.1016/j.annonc.2023.10.007
  46. Rugo HS, O’Shaughnessy J, Boyle F, et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study. Ann Oncol. 2022;33(6):616-27. doi: 10.1016/j.annonc.2022.03.006
  47. Hamilton EP, Kim JH, Eigeliene N, et al. Efficacy and safety results by age in monarchE: Adjuvant abemaciclib combined with endocrine therapy (ET) in patients with HR+, HER2-, node-positive, high-risk early breast cancer (EBC). J Clin Oncol. 2023;41(16_suppl.):501. doi: 10.1200/JCO.2023.41.16_suppl.501
  48. Mayer EL, Dueck AC, Martin M, et al. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2021;22(2):212-22. doi: 10.1016/S1470-2045(20)30642-2
  49. Kim S, Tiedt R, Loo A, et al. The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models. Oncotarget. 2018;9(81):35226-40. doi: 10.18632/oncotarget.26215
  50. Spring LM, Scarpetti L, Niemierko A, et al. Phase II study of adjuvant endocrine therapy with CDK4/6 inhibitor, ribociclib, for localized ER+/HER2- breast cancer (LEADER, part 1). Canc Res. 2022;82(4_Suppl.):P1-14-02-P1-14-02. doi: 10.1158/1538-7445.sabcs21-p1-14-02
  51. Spring L, Griffin C, Isakoff SJ, et al. Phase II study of adjuvant endocrine therapy with CDK4/6 inhibitor, ribociclib, for localized ER+/HER2- breast cancer (LEADER). J Clin Oncol. 2020;38(15_suppl.):531. doi: 10.1200/JCO.2020.38.15_suppl.531
  52. Peuker CA, Yaghobramzi S, Grunert C, et al. Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancer-findings from the RIBECCA trial. Eur J Cancer. 2022;162:45-55. doi: 10.1016/j.ejca.2021.11.025
  53. Rao P, Tullai J, Aspesi P, et al. Characterization of cancer cell lines made senescent by exposure to ribociclib, doxorubicin, or TGFβ1, and identification of genes required for entry into senescence and sensecent cell survival. In: AACR Annual Meeting. 10-15 April and 17-21 May. 2021.
  54. Riggio AI, Varley KE, Welm AL. The lingering mysteries of metastatic recurrence in breast cancer. Br J Cancer. 2021;124(1):13-26. doi: 10.1038/s41416-020-01161-4
  55. Tripathy D, S-a IM, Colleoni M, et al. Updated overall survival (OS) results from the phase III MONALEESA-7 trial of pre- and perimenopausal patients with HR+/HER2- advanced breast cancer (ABC) treated with endocrine therapy (ET) +/- ribociclib. San Antonio Breast Cancer Symposium, San Antionio, TX, 8-11, 2020.
  56. Hortobagyi G. Ribociclib + Nonsteroidal Aromatase Inhibitor as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer: Final Invasive Disease – Free Survival Analysis From the NATALEE Trial. Presented at SABCS 2023. GS03-03. Available at: http://www.sabcs.org. Accessed: 12.12.2023.
  57. Diéras V, Harbeck N, Joy AA, et al. Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2- Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial. Oncologist. 2019;24(12):1514-25. doi: 10.1634/theoncologist.2019-0019
  58. Slamon D, Stroyakovskiy D, Yardley D, et al. Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer: Primary results from the phase III NATALEE trial. J Clin Oncol. 2023;41(17_suppl.):LBA500. doi: 10.1200/JCO.2023.41.17_suppl.LBA500
  59. Burris HA, Chan A, Bardia A, et al. Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer. Br J Cancer. 2021;125(5):679-86. doi: 10.1038/s41416-021-01415-9

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Survival without invasive disease [56].

Download (94KB)
Indexing metadata
3. Fig. 2. Survival without distant metastasis [56].

Download (84KB)
Indexing metadata

Copyright (c) 2023 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 


Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».